Trial Profile

Phase 1 open label, single arm, dose escalation study of WP1066 adult patients with recurrent malignant glioma

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 25 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs WP 1066 (Primary)
Indications Glioma
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use

Most Recent Events

25 Apr 2022 New trial record
21 Apr 2022 According to a Moleculin Biotech media release, the US Food and Drug Administration (FDA) has cleared Investigational New Drug (IND) application to initiate this study.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com